# OnCo record hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hodgkin-lymphoma" ;
  schema:name "Hodgkin lymphoma"@en ;
  schema:description "Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."@en ;
  schema:url <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q209369> ;
  schema:citation <https://en.wikipedia.org/wiki/Hodgkin_lymphoma>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/types-lymphoma/hodgkin-lymphoma/classical-hodgkin-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment>, <https://lymphoma-action.org.uk/news/annual-breast-screening-missed-following-radiotherapy-hodgkin-lymphoma>, <https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols/protocols-for-surveillance-of-women-at-higher-risk-of-developing-breast-cancer>, <https://doi.org/10.1056/NEJMoa1505949>, <https://doi.org/10.1001/jamainternmed.2015.1180>, <https://www.nhs.uk/conditions/hodgkin-lymphoma/>, <https://www.nhs.uk/conditions/hodgkin-lymphoma/symptoms/>, <https://www.nhs.uk/conditions/hodgkin-lymphoma/treatment/>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/hodgkin-lymphoma>, <https://www.cancerresearchuk.org/about-cancer/hodgkin-lymphoma/living-with>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851> ;
  onco:tag "heme", "spike" ;
  onco:related <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/pairings/bleomycin-omission-caution/>, <https://onco.cc/biomarkers/pd-ligand-9p24-alteration/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/>, <https://onco.cc/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cytogenetics-fish/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/ciita/>, <https://onco.cc/targets/jak1/>, <https://onco.cc/targets/stat3/>, <https://onco.cc/targets/socs1/>, <https://onco.cc/targets/b2m/> ;
  onco:drugs <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/mechlorethamine/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/palifermin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/etoposide/> ;
  onco:companies <https://onco.cc/companies/haihe-biopharma/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/swog/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/companies/gbg/> ;
  onco:institutions <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/dana-farber/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/tumor-microenvironment/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/pathways/myeloid-suppression-axis/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-beacopp-or-abvd/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/lymphoma-living-scanxiety-and-surveillance/>, <https://onco.cc/terms/lymphoma-living-returning-to-work/>, <https://onco.cc/terms/lymphoma-living-vaccinations/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/lymphoma-bio-hodgkin-microenvironment/>, <https://onco.cc/terms/lymphoma-bio-ebv-latency/>, <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/> ;
  onco:trials <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/nct07188558/>, <https://onco.cc/trials/nct04002297/>, <https://onco.cc/trials/nct06230224/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/aethera/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/trials/hd10/>, <https://onco.cc/trials/hd16/>, <https://onco.cc/trials/hd18/>, <https://onco.cc/trials/ahl2011/>, <https://onco.cc/trials/eortc-h10/>, <https://onco.cc/trials/radar-hodgkin/> ;
  onco:journals <https://onco.cc/journals/hematological-oncology/>, <https://onco.cc/journals/journal-of-adolescent-and-young-adult-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/abexinostat/>, <https://onco.cc/drugs/mk-1045/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/rondecabtagene-autoleucel/>, <https://onco.cc/drugs/krt-232/>, <https://onco.cc/drugs/azd3470/>, <https://onco.cc/drugs/englumafusp-alfa/>, <https://onco.cc/drugs/azd4512/>, <https://onco.cc/drugs/jnj-90014496/>, <https://onco.cc/drugs/ctx112/>, <https://onco.cc/drugs/at101/>, <https://onco.cc/drugs/men1703/>, <https://onco.cc/drugs/cd19-t-hank/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/ideas/idea-chemo-free-hodgkin/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/trials/hd21/> ;
  onco:standardOfCare <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/pairings/bleomycin-omission-caution/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/aethera/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/trials/ahod1331/>, <https://onco.cc/trials/euronet-phl-c2/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-hepatitis-b-reactivation/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/strain-echocardiography-gls/>, <https://onco.cc/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/> .